Changes to the pharmaceutical Benefits Advisory Committee

Medical Journal of Australia

Volumn 174, Issue 5, 2001, Pages 209-210

  Henry, D A ^a   Birkett, D J ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; SILDENAFIL;

COST EFFECTIVENESS ANALYSIS; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG UTILIZATION; EDITORIAL; GOVERNMENT; HEALTH CARE POLICY; LAW; MEDICAL SOCIETY; PHARMACEUTICAL CARE; PROFIT;

EID: 0035809715     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2001.tb143234.x     Document Type: Editorial

References (28)

1. Meddling with drugs
2. Drugs scheme has its benefits
3. In the land down under, a model for national drug insurance
4. A dose of drama in debate on drugs
5. The Pharmaceutical Industry - To whom is it accountable?
6. Emerging standardization in pharmaco-economics
7. NICE to rule on influenza flu drug zanamivir
8. Drug firms stymied in the lab, become marketing machines
9. The biggest pushers of all
10. Glaxo attempts to block access to generic AIDS drugs in Ghana
11. A turning point that left millions behind
12. Cheap prescription drugs creating new brand of US tourist in Canada, Mexico
13. Drug makers on attack in Maine
14. Drug company threatens legal action over Canadian guidelines
15. Academia and industry: Lessons from the unfortunate events in Toronto
16. Thyroid storm
17. Viagra guidance declared unlawful
18. Drug companies and the Third World: A case study in neglect
19. Millions for Viagra. Pennies for the poor
20. Sickening sales pitch of the drug marketers
21. Is academic medicine for sale?